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Oral route has been the most popular route for sustained delivery of drugs because
of its convenience and ease of administration, greater flexibility in dosage form design.
Controlled release delivery systems provide a uniform concentration or amount of drug
at the absorption site and thus, after absorption, allow maintenance of plasma concen-
tration within a therapeutic range, which minimizes side effects and also reduces admini-
stration frequency. Chitosan is a linear hydrophilic polysaccharide polymer of D-gluco-
samine. Chitosan in the form of nanoparticulate systems has been already reported as a
promising carrier for the delivery of peptides, proteins, oligonucleotides and plasmids
(1–3).
Spray-drying is a technique that allows instantaneous drying of solutions, suspen-
sions or emulsions. It has been widely used in making nanoparticulate drug delivery
systems (4–6).
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The present investigation was undertaken to fabricate po-
rous nanoparticles of metoprolol tartrate by spray-dry-
ing using ammonium carbonate as pore former. Prepared
nanoparticles were coated with Eudragit S100 polymer
in order to prevent the release of metoprolol tartrate in
the upper GI tract. It was shown that nanoparticles with
low size ranges can be obtained with a low feed inlet rate.
Micromeritic studies confirmed that nanoparticle batches
are discrete and free flowing. Effects of the pore former
on drug loading, porosity and in vitro release were stud-
ied. It was found that there was an increase in drug load-
ing and porosity with increasing the amount of pore for-
mer. In vitro drug release studies showed that an increase
in pore former made drug release faster. Release kinetics
proved that nanoparticles follow a zero-order release me-
chanism.
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The presence of pores in ceramic foams offers the possibility of using these porous
ceramics as carriers for local and controlled delivery of drugs. Ammonium carbonate
(AC) has been already used as a pore former to produce porous microparticles of ben-
droflumethazide by spray-drying (7). Metoprolol tartrate (MT) is a b-selective adrener-
gic blocking agent and is prescribed widely in cardiovascular diseases such as hyperten-
sion, angina pectoris, arrhythmias and myocardial infarctions.
In the present study, spray-dried porous nanoparticles (NP) of metoprolol tartrate
(MT) were prepared using ammonium carbonate (AC) as pore former in order to main-
tain a constant plasma concentration within the desired period and ensure the desired
therapeutic response. Various factors, including the effect of inlet rate on particle size,
effect of pore former on the porosity of prepared nanoparticulate batches and the effect
on drug release, were investigated.
EXPERIMENTAL
Materials
Metoprolol tartrate was obtained as a gift sample from AstraZeneca Pvt. Ltd., India.
Chitosan was procured from Sigma Aldrich, India. Ammonium carbonate and directly
compressible microcrystalline cellulose (MCC) were procured from Loba Chemie Pvt.
Ltd., India. Eudragit S100 was received as a gift sample from Evonik Degussa Pvt. Ltd.,
India. Other reagents were of analytical grade.
Preparation of spray-dried porous nanoparticles
Chitosan solution in aqueous acetic acid was prepared under continuous magnetic
stirring. To the prepared chitosan solution, ammonium carbonate (pore former) was ad-
ded under stirring to get the final spray-drying solution. Polyvinyl alcohol (PVA), in
varying concentrations, had been added to the spray-drying solution as an emulsion sta-
bilizer. Prepared solution was spray-dried with a Büchi 290 spray-dryer (Büchi, Switzer-
land) operating in the closed mode, using the Büchi 295 inert loop and nitrogen as the
drying gas under standard operating conditions (7). Each formulation was prepared in
triplicate (Table I).
Drug loading of metoprolol tartrate in porous NP batches
Loading of MT was done through incubating NP batches in a 3 % (m/V) drug solu-
tion under mild agitation at room temperature. The loading capacity of uncoated parti-
cles was calculated in an indirect way, quantifying the amount of MT that remained in
solution.
Coating of porous nanoparticles
Enteric coating of all NP formulations bearing MT was done by spray coating in a
conventional coating pan (8). In brief, the coating solution was prepared by mixing Eu-
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dragit S100 with acetone for 1 h using a stirrer. After an hour, triethyl citrate (TEC) 2 %
was added and stirring was continued for 30 min. The NPs were coated in a conven-
tional pan at 20 rpm, at a coating solution spray rate of 2 mL min–1 and inlet tempera-
ture of 60 °C. Coating of NP batches was continued till the mass gain was 2 % per aver-
age mass of the NP in the pan. The coated NP batches were dried in an oven at 35 °C for
one day and stored in an air-tight container.
Micromeritic properties
Both poured (or fluff) bulk (Do) and tapped bulk densities (DF) were determined
with a 10-mL graduated cylinder using a bulk density apparatus. Angle of repose was
calculated by the fixed funnel method and in vitro porosity was computed and was ex-
pressed in percentage (9).
Drug content
For drug content uniformity NPs (100 mg) were crushed and then transferred into a
250-mL volumetric flask. The volume was adjusted with pH 7.4 phosphate buffer and
kept on a rotary shaker for 24 h in order to completely extract the drug. The mixture was
filtered, and the drug was assayed spectrophotometrically at 222 nm using a Shimadzu
UV-1800 instrument (Japan).
Particle size and zeta potential of prepared nanoparticles
Size and zeta potential of MT loaded NPs were measured by photon correlation spec-
troscopy (PCS) using a Zetasizer Nano ZS (Malvern Instruments, UK). The particle size
analysis was performed at a scattering angle of 90 °C at room temperature. Concentra-
tion of the particles was adjusted to an appropriate value by pure water filtered through
a 0.22-mmmembrane. The diameter was averaged from three parallel measurements and
expressed as mean ± standard deviation.
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CH1 1: 0.15 2 1
CH2 1: 0.45 2 1
CH3 1: 0.75 2 1
CH4 1: 0.15 2 2
CH5 1.5: 0.45 2 2
CH6 1.5: 0.75 2 2
CH7 2: 0.15 2 4
CH8 2: 0.45 2 4
CH9 2: 0.75 2 4
PVA – polyvinyl alcohol
Fourier transform infrared radiation measurements (FTIR)
FTIR analysis was carried out for pure drug and for the formulation using the KBr
pellet method on a FTIR spectrophotometer type Shimadzu model 8033 in order to as-
certain compatibility between the drug and polymer used.
Gel permeation chromatography
Molecular mass measurements were carried out using size exclusion chromatogra-
phy (GPC) (pump Waters model 501, injector Waters model U6K, USA). Commercially
available Bio-Gel TSK columns (ToyoSoda, Japan) were used. A Knauer HPLC pump Ty-
pe 64.00 and Rheodyne injector were used, with a refractive index detector Model ERC
7512 (Erma CR., Inc., Japan).
Differential scanning calorimetry (DSC)
All dynamic DSC studies were carried out on a DuPont 900 differential thermal ana-
lyzer (USA). The instrument was calibrated using high purity indium metal as standard.
Dynamic scans were taken in a nitrogen atmosphere at the heating rate of 10 °C min–1.
Scanning electron microscopy (SEM)
SEM photographs were taken with a scanning electron microscope Model Jeol, Ja-
pan, LV-5600, at the required magnification at room temperature. The photographs were
studied to visualize the porous structure of the MT loaded NPs.
Transmission electron microscopic study (TEM)
TEM was used to observe the morphology of MT loaded NPs. Sample was first di-
luted and a drop was placed onto a carbon coated copper grid and dried in an oven at
40 °C for 15 min. The images were taken using a Hitachi, Japan Ultra-thin film evalua-
tion system (HD-2300A) in phase contrast, Z contrast, secondary electron modes.
X-ray powder diffraction (XRPD)
X-ray powder diffraction patterns were recorded at room temperature with a D8 Ad-
vance wide-angle diffractometer (Bruker AXS, Germany) in the range of 5–40° of 2q.
Tablets for XRPD analysis were made with KBr and analyzed with an IR Perkin-Elmer
model 1420, in the range from 4000 to 600 cm–1.
In vitro drug release studies and validation of UV-spectroscopic method
In vitro drug release studies were performed using a USP (10) dissolution rate appa-
ratus (apparatus 1, 100 rpm, 37 ± 0.5 °C) in pH 1.2 hydrochloric acid buffer (900 mL) for 2 h
as the average gastric emptying time. Then, the dissolution medium was replaced with a
pH 7.4 phosphate buffer (900 mL) for the rest of the dissolution studies till complete
drug release was obtained. MT loaded NPs equivalent to 50 mg of drug were placed into
a dialysis bag (cut-off 50,000 Da). The amount of MT released from the NPs at different
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time intervals was determined spectrophotometrically at 222 nm. All experiments were
done in triplicate.
Validation of the analytical method for MT quantification was performed according
to the method adopted by Baloðlu and Þenyiðit (11) with slight modifications. Specifity
tests finally proved that there was no interference between the polymers and MT. Re-
sults show a relative standard deviation (RSD) less than 0.5 and 1.3 % indicating good
repeatability and reproducibility, respectively.
Release kinetics and mechanism
In order to analyze the drug release mechanism, in vitro release data were fitted into
various drug release models such as zero-order, first order, Higuchi, Hixon-Crowell cube
root law and Korsmeyer-Peppas model (12–14).
RESULTS AND DISCUSSION
Effect of feed inlet rate on nanoparticle size
In the spray-drying process, the function of the peristaltic pump is to carry the poly-
mer solution to the nozzle. This parameter could considerably influence the efficacy of
the drying process (15). To see the effect, formulation batches were spray dried at differ-
ent feed inlet rates (0.5, 3 and 6 mL min–1) so as to see the effect of the inlet feed rate on
particle size. It was clearly observed that low pump values yielded the best results with
regard to nanoparticulate morphology (data not shown). Use of the 0.5 mL min–1 inlet
rate led to formation of discrete spherical particles characterized by a smooth surface.
This may be attributed to the fact that during the spray-drying process, high pump
rates result in a large volume of spraying solution to be dried, but heated air might not
transform liquid droplets into solid droplets immediately leading to the formation of bigger
irregular-shape particles that are not completely dried and tend to form aggregates (16, 17).
In short, the pump inlet rate influences the particle size and morphology. Thus, to
keep the particle size within a small range, the inlet feed pump rate should be kept low
because an increase in flow leads to an increase in the mean diameter of particles from
0.368 nm (at 0.5 mL min–1) to 4.89 nm (at 6 mL min–1).
Micromeritic properties
Micromeritic properties for prepared nanoparticles are shown in Table II. It was fo-
und that the presence of a pore former affects the nanoparticle density and % porosity.
For CH1 to CH9 formulations bulk density varies from 0.287 ± 0.027 to 0.219 ± 0.017, tap
density from 0.83 ± 0.02 to 0.57 ± 0.26 and porosity from 63.1 to 79.2 %. Angle of repose
shows a good flowing property of prepared batches of nanoparticles. Due to the pres-
ence of the pore forming agent, there was variation in the density parameter; density of
the formulation decreased (CH1 to CH3) and porosity of the nanoparticles batches in-
creased with increased concentration of the pore forming agent. The same phenomenon
was observed for other batches.
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Effect of pore former on drug loading
There was a considerable effect of the pore forming agent on drug loading efficiency
of prepared nanoparticle batches. In case of CH1 to CH3, drug loading varied between
42.3 ± 1.7 and 74.7 ± 1.6 %. Drug loading increased as the concentration of the pore form-
ing agent increased. The same observation applies to other batches. For CH4 to CH6
drug loading varies between 44.7 ± 1.1 and 77.3 ± 1.1 % and for CH6 to CH9 between
51.3 ± 1.2 and 81.3 ± 1.4 %. There was a slight increase in drug loading efficiency for CH6
to CH9 compared to other batches. This may be attributed to the fact that higher concen-
tration of chitosan present here holds a higher amount of drug within its matrix.
FTIR and DSC
Nanoparticulate batches CH7 to CH9 were taken into consideration as suitable for-
mulations because of their small size, high zeta potential compared to other formulated
batches and ability to prolong the drug release rate for a particular period of time. Among
them, formulation CH8 was randomly chosen for DSC and FTIR studies.
The DSC thermogram for pure drug showed a sharp endotherm at 122.9 °C, which
corresponds to its melting. Thermogram of the formulation showed the endotherm at
121.9 °C, as shown in Fig. 1a. Physical mixture showed a broadened peak at the same
temperature. This reveals that there was no interaction between the drug and excipients
used.
Metoprolol tartrate exhibited a broad band at 3440.77 cm–1 for aliphatic C-H stretch.
In case of the formulation, a peak occurs at 3438.37 cm–1 for aliphatic C-H stretch. Physi-
cal mixture showed a peak value of 3439.33 cm–1 corresponding to the C-H stretch, as
shown in Fig. 1b, thus ruling out any interactions between the drug, polymer and excipi-
ents used.
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CH1 0.287 ± 0.027 0.83 ± 0.02 23.13 ± 1.86 63
CH2 0.261 ± 0.046 0.77 ± 0.04 22.16 ± 2.56 67.9
CH3 0.233 ± 0.016 0.70 ± 0.16 22.29 ± 1.37 73.3
CH4 0.293 ± 0.026 0.71 ± 0.23 26.18 ± 1.81 64.6
CH5 0.271 ± 0.062 0.69 ± 0.11 23.31 ± 1.53 71.7
CH6 0.254 ± 0.087 0.65 ± 0.19 24.21 ± 2.76 78.3
CH7 0.295 ± 0.061 0.75 ± 0.22 21.20 ± 2.16 65.2
CH8 0.256 ± 0.049 0.63 ± 0.17 26.17 ± 2.06 72.3
CH9 0.219 ± 0.017 0.57 ± 0.26 27.23 ± 1.17 79.2
Mean ± SD, n = 3.
SEM, TEM and zeta potential
Nanoparticle surface morphology and shape were investigated using SEM and TEM
analyses. SEM images completely revealed that the drug loaded nanoparticles were dis-
tinct, spherical, having a porous surface (Fig. 2a).
However, in case of nanoparticulate batches having higher concentration of the pore
forming agent, the surface of nanoparticles was found to be rough because of the large
amount of pores formed due to the leaching out of ammonium carbonate from the ma-
trix of nanoparticles during the vaporized process (18).
TEM analysis (Fig. 2b) is in conformity with SEM analysis, showing the spherical
shape of prepared nanoparticles with homogeneous drug distribution within the nano-
particles prepared. Since from SEM and TEM analyses it was clearly seen that there was
no surface drug present on nanoparticles or there was no accumulation of drug particles
on the surface or within its matrix, so it can be said that the drug is homogeneously dis-
tributed in nanoparticles.
Zeta potential was found to be in the range from –11.9 ± 0.8 to –21.3 ± 1.7 for CH1 to
CH9 formulations. In general, particle aggregation is less liklely to occur for charged par-
ticles (high zeta potential) due to electric repulsion. Lower zeta potential facilitates ag-
gregation of nanoparticles. Strong negative charge may provide a basis for the overall
high stability of the nanopracticles suspension.
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Fig. 1. a) DSC and b) FTIR spectra of: pure drug (a), formulation CH8 (b) and physical mixture (c)
of metoprolol tartrate, chitosan, ammonium carbonate and Eudragit S100.
Size distribution
Average size of prepared nanoparticles varied between 687.0 ± 1.3 and 317.0 ± 2.1
nm with a polydispersity index ranging from 0.767 ± 0.003 to 0.354 ± 0.034 (Table III).
Zeta potential for all nanoparticle formulations was found to be high indicating stability
of nanoparticles.
X-ray powder diffraction
Fig. 3 shows the XRPD pattern of pure MT and of nanoparticles prepared by the
spray-drying method. XRPD of pure MT show distinctive peaks that indicate high cry-
stallinity of MT. MT peaks are hardly observed in the formulation diffractogram. Disap-
pearance of crystalline peaks of the drug in the prepared nanoparticulate batches indi-
cates an amorphous state of the drug in the spray-dried formulations.
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Fig. 2. a) SEM and b) TEM analysis of CH8 formulation.









CH1 0.767 ± 0.003 687 ± 1.3 –11.9 ± 0.8
CH2 0.717 ± 0.013 673 ± 0.3 –12.6 ± 1.2
CH3 0.759 ± 0.022 654 ± 1.7 –12.3 ± 1.5
CH4 0.747 ± 0.011 584 ± 2.5 –13.8 ± 2.3
CH5 0.713 ± 0.035 571 ± 1.7 –14.1 ± 0.7
CH6 0.653 ± 0.021 554 ± 0.8 –13.7 ± 1.8
CH7 0.378 ± 0.091 321 ± 1.4 –21.3 ± 1.6
CH8 0.398 ± 0.027 343 ± 1.1 –21.2 ± 2.1
CH9 0.354 ± 0.034 317 ± 2.1 –21.3 ± 1.7
Gel permeation chromatography
Gel permeation chromatography analysis was carried out in order to establish and
verify if the conditions employed during the spray-drying process caused any chitosan
degradation. Data obtained after GPC analysis showed that no/negligible change in poly-
mer molecular mass occured after spray-drying of chitosan. Molecular mass of chitosan
was 5,000 before spray-drying and it was found to be the same after spray-drying. The
average molecular mass and polydispersity index of the polymer before the spray-dry-
ing process, as well as those of the polymer after spray-drying and of the polymer with
drug, were determined and no changes were found.
Effects of pore forming agent and polymer concentration on drug release
Drug release of all prepared porous nanoparticulate batches is shown in Fig. 4. It is
clearly shown that from all batches of porous nanoparticles, no drug release took place
in the first 2 h at pH 1.2 because of the enteric coating by Eudragit S100. This shows that
enteric coating by Eudragit S100 (2 %, m/V) efficiently prevents drug release from po-
rous NPs at gastric pH 1.2. Drug release started after changing the dissolution media pH
to 7.4. Dissolution of the enteric coat brings the porous nanoparticle surface in direct con-
tact with the dissolution media. Drug was released in a controlled manner due to the hy-
dration ability of chitosan, which on coming in contact with media leads to the forma-
tion of a gelatinous mass that acts as retardant material for the drug to diffuse out.
Effect of the pore forming agent was investigated so as to see the impact of pores
formed that will affect the drug release. In case of formulations CH1 to CH3, drug relea-
se was found to be rapid. It was observed that within a period of 8 h maximum drug was
released by nanoparticles CH1 (95.2 ± 1.3 %), CH2 (99.8 ± 1.3 %) and CH3 (98.9 ± 1.3 %).
However, release took place in a linear fashion. CH1 and CH2 released maximum amo-
unt of the drug in 8 h, whereas CH3 was not able to sustain the drug release for 8 h. This
may be attributed to the fact of increased pore forming agent concentration and smaller
quantity of polymer used in the formulation which is not able to hold the drug within its
matrix for a long time. On increasing the concentration of the pore forming agent, drug
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Fig. 3. XRPD diffraction patterns of: a) pure drug, b) formulation CH8, c) physical mixture of meto-
prolol tartrate, chitosan, ammonium carbonate and Eudragit S100.
release will increase because there will be more porous surface available for the drug to
diffuse out.
The same effect was observed in case of other batches. But these batches were able
to sustain the drug release up to 12 h, which is preferable for maintaining the drug
concentration for a long period of time. Drug release at the end of 12 h was found to be
94.2 ± 2.6 for CH4 and 98.8 ± 2.1 for CH5. CH6 was not able to sustain the drug release
for 12 h and released the maximum amount of drug load after 11 h (98.9 ± 1.8 %). Sus-
tained effect was due to the increased amount of polymer prolonging the time for drug
release.
In case of polymeric nanoparticles (CH7 to CH9), it was found that the prepared
batches were able to sustain the drug release even for 18 h: CH7 96.2 ± 1.7 %, CH8
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Fig. 4. In vitro drug release profile of all batches of MT loaded NPs mean ± SD, n = 3.




Peppas (n)Zero-order First order Higuchi
CH1 0.9686 0.6956 0.7984 2.125
CH2 0.9673 0.8125 0.8115 2.698
CH3 0.9745 0.8513 0.8298 2.355
CH4 0.9769 0.7874 0.8347 2.425
CH5 0.9731 0.8125 0.8426 2.278
CH6 0.9786 0.8347 0.7311 2.358
CH7 0.9687 0.7891 0.7228 2.336
CH8 0.9645 0.8042 0.6713 2.547
CH9 0.9666 0.8188 0.8514 2.358
98.8 ± 1.8 % and CH9 96.9 ± 2.4 %. Hence, it can be concluded that the more the polymer
used, the more sustained drug delivery can be obtained. Maintaining a desired polymer
to pore forming agent ratio, a desired drug release profile can be achieved.
Release kinetics
Release kinetics of the porous nanoparticles prepared is shown in Table IV. The best
fit model representing the drug release from porous nanoparticles was of the zero-order.
This is further confirmed by the Korsmeyer-Peppas model; the value of n is greater than
1, showing case II drug release or anomalous drug release, indicating that two or more
drug release mechanisms are involved, that is, diffusion and erosion.
CONCLUSIONS
Porous nanoparticles of metoprolol tartrate were obtained by spray-drying of chito-
san solution using ammonium carbonate as a pore forming agent. Chitosan can be used
as a carrier for the low dosed delivery system for single dose administration of metop-
rolol tartrate. Studies show that using a low pump inlet rate, small sized particles can be
produced. Drug was successfully incorporated in porous nanoparticles by the dipping
method, which can be used for many other, water-soluble drugs where drug entrapment
is a tedious process. GPC clearly showed that chitosan was not degraded in terms of its
molecular mass and could be used to produce spray-dried nanoparticles. DSC and FTIR
studies showed that the drug and polymer used are compatible, ruling out any interac-
tions. SEM confirmed the formation of open pores, which allow the media to easily go
inside the porous structure of nanoparticles. TEM is in conformity with SEM studies. In
vitro drug release studies showed that drug loaded nanoparticles were able to sustain
the delivery of the drug even for 18 hours.
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S A @ E TA K
Porozne nano~estice metoprolol tartarata dobivene pomo}u su{enja
sprejanjem: Razvoj, karakterizacija i evaluacija in vitro
MOHAMMED S. KHAN, GOWDA D. VISHAKANTE i HOSAKOTE G. SHIVAKUMAR
U radu je opisana priprava poroznih nano~estica metoprolol tartarata pomo}u su{e-
nja sprejanjem, koriste}i amonijev karbonat za stvaranje pora. Da bi se sprije~ilo osloba-
|anje metoprolol tartarata u gornjem dijelu GI trakta, nano~estice su oblo`ene polime-
rom Eudragit S100. Nano~estice podjednake veli~ine mogu se dobiti polaganim uklapanjem
ljekovite tvari. Mikromeri~ke studije potvrdile su da su nano~estice zasebne i te~ne. Prou-
~avan je utjecaj sredstva za stvaranje pora na koli~inu uklopljenog lijeka, poroznost i in
vitro osloba|anje. Pove}anje koli~ine sredstva za stvaranje pora pove}ava koli~inu uklop-
ljenog lijeka, poroznost i brzinu osloba|anja ljekovite tvari. Osloba|anje metoprolola slije-
di kinetiku nultog reda.
Klju~ne rije~i: metoprolol tartarat, porozne nano~estice, su{enje sprejanjem, gel permeacijska kroma-
tografija
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